Impact of PCSK9, WDR12, CDKN2A, and CXCL12 Polymorphisms in Jordanian Cardiovascular Patients on Warfarin Responsiveness and Sensitivity

References

• Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2008;133(6):160S–198S. doi:10.1378/chest.08-0670
   PubMed Web of Science ®Google Scholar
• Kim Y, Smith A, Wu AH. C3435T polymorphism of MDR1 gene with warfarin resistance. Clin Chim Acta. 2013;425:34–36. doi:10.1016/j.cca.2013.07.010
   PubMed Web of Science ®Google Scholar
• Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119(1):8S–21S. doi:10.1378/chest.119.1_suppl.8S
   PubMed Web of Science ®Google Scholar
• Eriksson N, Wallentin L, Berglund L, et al. Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. Pharmacogenomics. 2016;17(13):1425–1439. doi:10.2217/pgs-2016-0061
   PubMed Web of Science ®Google Scholar
• Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004;427(6974):537–541. doi:10.1038/nature02214
   PubMed Web of Science ®Google Scholar
• Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1—rationale and perspectives. Thromb Res. 2007;120(1):1–10. doi:10.1016/j.thromres.2006.10.021
   PubMed Web of Science ®Google Scholar
• Ravina E. The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs. John Wiley & Sons; 2011.
   Google Scholar
• Hirsh J. American Heart Association/American College of Cardiology foundation guide to warfarin therapy. J Am Coll Cardiol. 2003(41):1633–1652.
   PubMed Web of Science ®Google Scholar
• Visser LE, Bleumink GS, Trienekens PH, et al. The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants. Br J Haematol. 2004;127(1):85–89. doi:10.1111/j.1365-2141.2004.05162.x
   PubMed Web of Science ®Google Scholar
• Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3):204S–233S. doi:10.1378/chest.126.3_suppl.204S
   PubMed Web of Science ®Google Scholar
• Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score. J Am Coll Cardiol. 2011;57(2):173–180. doi:10.1016/j.jacc.2010.09.024
   PubMed Web of Science ®Google Scholar
• AL-Eitan L, Almasri A, Khasawneh R. Impact of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation therapy. Genes. 2018;9(12):578. doi:10.3390/genes9120578
   PubMed Web of Science ®Google Scholar
• Al-Eitan LN, Almasri AY, Al-Habahbeh SO. Impact of a variable number tandem repeat in the CYP2C9 promoter on warfarin sensitivity and responsiveness in Jordanians with cardiovascular disease. Pharmgenomics Pers Med. 2019;12:15–22. doi:10.2147/PGPM.S189838
   PubMed Web of Science ®Google Scholar
• Hughes DA, Pirmohamed M. Warfarin Pharmacogenetics. Springer; 2007:899–902.
   Google Scholar
• Li C, Schwarz UI, Ritchie MD, et al. Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood. 2009;113(17):3925–3930. doi:10.1182/blood-2008-09-176859
   PubMed Web of Science ®Google Scholar
• Xie H-G, Frueh FW. Pharmacogenomics Steps Toward Personalized Medicine. Per Med. 2005;2(4):325–337. doi:10.2217/17410541.2.4.325.
   Google Scholar
• AL-Eitan LN, Tarkhan AH. Practical challenges and translational issues in pharmacogenomics and personalized medicine from 2010 onwards. Curr Pharmacogenomics Person Med. 2017;14(1):7–17. doi:10.2174/1875692115666161215103842
   Google Scholar
• Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci. 2007;32(2):71–77. doi:10.1016/j.tibs.2006.12.008
   PubMed Web of Science ®Google Scholar
• Huijgen R, Boekholdt SM, Arsenault BJ, et al. RETRACTED: plasma PCSK9 levels and clinical outcomes in the TNT (treating to new targets) trial: a nested case-control study. J Am Coll Cardiol. 2012;59(20):1778–1784. doi:10.1016/j.jacc.2011.12.043
   PubMed Web of Science ®Google Scholar
• Hölzel M, Rohrmoser M, Schlee M, et al. Mammalian WDR12 is a novel member of the Pes1–Bop1 complex and is required for ribosome biogenesis and cell proliferation. J Cell Biol. 2005;170(3):367–378. doi:10.1083/jcb.200501141
   PubMed Web of Science ®Google Scholar
• Blattmann P, Schuberth C, Pepperkok R, et al. RNAi–based functional profiling of loci from blood lipid genome-wide association studies identifies genes with cholesterol-regulatory function. PLoS Genet. 2013;9(2):e1003338. doi:10.1371/journal.pgen.1003338
   PubMed Web of Science ®Google Scholar
• Zabalza M, Subirana I, Lluis-Ganella C, et al. Association between coronary artery disease genetic variants and subclinical atherosclerosis: an association study and meta-analysis. Rev Esp Cardiol. 2015;68(10):869–877. doi:10.1016/j.rec.2014.10.023
   PubMed Web of Science ®Google Scholar
• Kathiresan S, Voight BF, Purcell S, et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet. 2009;41(3):334–341.
   PubMed Web of Science ®Google Scholar
• Schunkert H, König IR, Kathiresan S, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011;43(4):333–338. doi:10.1038/ng.784
   PubMed Web of Science ®Google Scholar
• Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. N Eng J Med. 2007;357(5):443–453. doi:10.1056/NEJMoa072366
   PubMed Web of Science ®Google Scholar
• Lettre G, Palmer CD, Young T, et al. Genome-wide association study of coronary heart disease and its risk factors in 8090 African Americans: the NHLBI CARe Project. PLoS Genet. 2011;7(2):e1001300. doi:10.1371/journal.pgen.1001300
   PubMed Web of Science ®Google Scholar
• Farouk SS, Rader DJ, Reilly MP, et al. CXCL12: a new player in coronary disease identified through human genetics. Trends Cardiovasc Med. 2010;20(6):204–209. doi:10.1016/j.tcm.2011.08.002
   PubMed Web of Science ®Google Scholar
• Consortium IWP. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Eng J Med. 2009;360(8):753–764.
   PubMed Web of Science ®Google Scholar
• Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287(13):1690–1698. doi:10.1001/jama.287.13.1690
   PubMed Web of Science ®Google Scholar
• Al-Eitan LN, Almasri AY, Khasawneh RH. Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy. Saudi Pharm J. 2019;27(4):484–490. doi:10.1016/j.jsps.2019.01.011
   PubMed Web of Science ®Google Scholar
• Xu C, Wang F, Wang B, et al. Minor allele C of chromosome 1p32 single nucleotide polymorphism rs11206510 confers risk of ischemic stroke in the Chinese Han population. Stroke. 2010;41(8):1587–1592. doi:10.1161/STROKEAHA.110.583096
   PubMed Web of Science ®Google Scholar
• Lv X, Zhang Y, Rao S, et al. Joint effects of genetic variants in multiple loci on the risk of coronary artery disease in Chinese Han subjects. Circ J. 2012; 76(8):1987–1992. doi:10.1253/circj.cj-12--0156.
   Web of Science ®Google Scholar
• Cai G, Yu L, Huang Z, et al. Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population. Lipids Health Dis. 2018;17(1):213. doi:10.1186/s12944-018-0859-5
   PubMed Web of Science ®Google Scholar
• Schunkert H, Erdmann J, Samani NJ. Genetics of myocardial infarction: a progress report. Eur Heart J. 2010;31(8):918–925. doi:10.1093/eurheartj/ehq038
   PubMed Web of Science ®Google Scholar
• Dimova DK, Dyson NJ. The E2F transcriptional network: old acquaintances with new faces. Oncogene. 2005;24(17):2810–2826. doi:10.1038/sj.onc.1208612
   PubMed Web of Science ®Google Scholar
• Pilbrow AP, Folkersen L, Pearson JF, et al. The chromosome 9p21. 3 coronary heart disease risk allele is associated with altered gene expression in normal heart and vascular tissues. PLoS One. 2012;7(6):e39574. doi:10.1371/journal.pone.0039574
   PubMed Web of Science ®Google Scholar
• Döring Y, Pawig L, Weber C, et al. The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease. Front Physiol. 2014;5:212. doi:10.3389/fphys.2014.00212
   PubMed Web of Science ®Google Scholar